Metropolitan Life Insurance CO Amicus Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

  • $281 Million
  • Q3 2024

Shares

56 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
SELL
$11.43 - $14.24 $7,075 - $8,814
-619 Reduced 3.83%
15,529 $182,000
Q3 2023

Nov 14, 2023
BUY
$11.78 - $13.86 $12,098 - $14,234
1,027 Added 6.79%
16,148 $196,000
Q2 2023

Aug 10, 2023
BUY
$10.72 - $13.3 $3,794 - $4,708
354 Added 2.4%
15,121 $189,000
Q1 2023

May 15, 2023
SELL
$10.91 - $13.54 $23,947 - $29,720
-2,195 Reduced 12.94%
14,767 $163,000
Q4 2022

Jun 14, 2023
BUY
$9.89 - $12.7 $21,708 - $27,876
2,195 Added 14.86%
16,962 $207 Million
Q4 2022

Mar 30, 2023
BUY
$9.89 - $12.7 $7,882 - $10,121
797 Added 4.93%
16,962 $207,000
Q4 2022

Feb 15, 2023
BUY
$9.89 - $12.7 $7,882 - $10,121
797 Added 4.93%
16,962 $207,000
Q3 2022

Jun 14, 2023
BUY
$9.82 - $12.75 $13,728 - $17,824
1,398 Added 9.47%
16,165 $169 Million
Q2 2022

Jun 20, 2023
BUY
$6.23 - $11.12 $8,709 - $15,545
1,398 Added 9.47%
16,165 $173,000
Q1 2022

Jun 20, 2023
BUY
$7.89 - $12.48 $11,030 - $17,447
1,398 Added 9.47%
16,165 $153,000
Q1 2022

Mar 30, 2023
SELL
$7.89 - $12.48 $409,893 - $648,348
-51,951 Reduced 76.27%
16,165 $153,000
Q1 2022

May 12, 2022
SELL
$7.89 - $12.48 $409,893 - $648,348
-51,951 Reduced 76.27%
16,165 $153,000
Q4 2021

Jun 21, 2023
BUY
$9.82 - $12.44 $523,887 - $663,661
53,349 Added 361.27%
68,116 $786,000
Q4 2021

Mar 30, 2023
SELL
$9.82 - $12.44 $16,114 - $20,414
-1,641 Reduced 2.35%
68,116 $786,000
Q4 2021

Feb 15, 2022
SELL
$9.82 - $12.44 $16,114 - $20,414
-1,641 Reduced 2.35%
68,116 $787,000
Q3 2021

Jun 21, 2023
BUY
$8.74 - $11.84 $480,612 - $651,081
54,990 Added 372.38%
69,757 $666,000
Q3 2021

Mar 30, 2023
SELL
$8.74 - $11.84 $48,777 - $66,079
-5,581 Reduced 7.41%
69,757 $666,000
Q3 2021

Nov 15, 2021
SELL
$8.74 - $11.84 $48,777 - $66,079
-5,581 Reduced 7.41%
69,757 $666,000
Q2 2021

Jun 21, 2023
BUY
$8.71 - $10.72 $527,573 - $649,321
60,571 Added 410.18%
75,338 $726,000
Q2 2021

Mar 30, 2023
BUY
$8.71 - $10.72 $42,374 - $52,152
4,865 Added 6.9%
75,338 $726,000
Q2 2021

Aug 16, 2021
BUY
$8.71 - $10.72 $655,584 - $806,872
75,268 Added 107525.71%
75,338 $726,000
Q1 2021

Jun 26, 2023
BUY
$9.2 - $23.86 $512,495 - $1.33 Million
55,706 Added 377.23%
70,473 $696 Million
Q1 2021

Mar 30, 2023
SELL
$9.2 - $23.86 $24,287 - $62,990
-2,640 Reduced 3.61%
70,473 $696,000
Q1 2021

May 14, 2021
SELL
$9.2 - $23.86 $671,995 - $1.74 Million
-73,043 Reduced 99.9%
70 $696,000
Q4 2020

Jun 22, 2023
BUY
$13.47 - $24.89 $785,920 - $1.45 Million
58,346 Added 395.11%
73,113 $1.69 Million
Q4 2020

Mar 30, 2023
SELL
$13.47 - $24.89 $3,838 - $7,093
-285 Reduced 0.39%
73,113 $1.69 Million
Q4 2020

Feb 16, 2021
SELL
$13.47 - $24.89 $3,838 - $7,093
-285 Reduced 0.39%
73,113 $1.69 Million
Q3 2020

Jun 26, 2023
BUY
$12.89 - $15.89 $755,753 - $931,646
58,631 Added 397.04%
73,398 $1.04 Million
Q3 2020

Mar 30, 2023
SELL
$12.89 - $15.89 $70,443 - $86,838
-5,465 Reduced 6.93%
73,398 $1.04 Million
Q3 2020

Nov 13, 2020
SELL
$12.89 - $15.89 $70,443 - $86,838
-5,465 Reduced 6.93%
73,398 $1.04 Million
Q2 2020

Jun 26, 2023
BUY
$8.86 - $15.69 $567,890 - $1.01 Million
64,096 Added 434.05%
78,863 $1.19 Million
Q2 2020

Mar 30, 2023
BUY
$8.86 - $15.69 $25,862 - $45,799
2,919 Added 3.84%
78,863 $1.19 Million
Q2 2020

Aug 14, 2020
BUY
$8.86 - $15.69 $25,862 - $45,799
2,919 Added 3.84%
78,863 $1.19 Million
Q1 2020

Jul 12, 2023
BUY
$6.63 - $11.16 $412,816 - $694,877
62,265 Added 421.65%
77,032 $711,000
Q1 2020

Mar 30, 2023
SELL
$6.63 - $11.16 $24,371 - $41,024
-3,676 Reduced 4.62%
75,944 $701,000
Q1 2020

May 15, 2020
SELL
$6.63 - $11.16 $24,371 - $41,024
-3,676 Reduced 4.62%
75,944 $702,000
Q4 2019

Jul 12, 2023
BUY
$7.48 - $10.75 $485,100 - $697,169
64,853 Added 439.18%
79,620 $775,000
Q4 2019

Mar 30, 2023
SELL
$7.48 - $10.75 $16,396 - $23,564
-2,192 Reduced 2.68%
79,620 $775,000
Q4 2019

Feb 14, 2020
SELL
$7.48 - $10.75 $16,396 - $23,564
-2,192 Reduced 2.68%
79,620 $775,000
Q3 2019

Jul 12, 2023
BUY
$8.02 - $13.25 $537,700 - $888,346
67,045 Added 454.02%
81,812 $656,000
Q3 2019

Mar 30, 2023
BUY
$8.02 - $13.25 $161,835 - $267,371
20,179 Added 32.74%
81,812 $656,000
Q3 2019

Nov 14, 2019
BUY
$8.02 - $13.25 $161,835 - $267,371
20,179 Added 32.74%
81,812 $656,000
Q2 2019

Jul 12, 2023
BUY
$10.96 - $14.4 $539,341 - $708,624
49,210 Added 333.24%
63,977 $798,000
Q1 2019

Jul 13, 2023
BUY
$10.04 - $13.92 $470,534 - $652,374
46,866 Added 317.37%
61,633 $838,000
Q1 2019

Mar 30, 2023
BUY
$10.04 - $13.92 $448,496 - $621,820
44,671 Added 263.36%
61,633 $838,000
Q1 2019

May 16, 2019
BUY
$10.04 - $13.92 $516,588 - $716,225
51,453 Added 505.43%
61,633 $838,000
Q1 2019

May 15, 2019
SELL
$10.04 - $13.92 $516,588 - $716,225
-51,453 Reduced 83.48%
10,180 $886,000
Q4 2018

Jul 13, 2023
BUY
$8.38 - $13.44 $392,737 - $629,879
46,866 Added 317.37%
61,633 $590,000
Q4 2018

Feb 14, 2019
BUY
$8.38 - $13.44 $398,569 - $639,233
47,562 Added 338.01%
61,633 $590,000
Q3 2018

Jul 13, 2023
BUY
$11.6 - $16.54 $543,645 - $775,163
46,866 Added 317.37%
61,633 $745 Million
Q3 2018

Nov 14, 2018
SELL
$11.6 - $16.54 $551,719 - $786,675
-47,562 Reduced 77.17%
14,071 $170,000
Q2 2018

Aug 15, 2018
BUY
$13.13 - $17.09 $13,773 - $17,927
1,049 Added 1.73%
61,633 $0
Q1 2018

May 15, 2018
BUY
$13.76 - $17.12 $115,749 - $144,013
8,412 Added 16.12%
60,584 $0
Q4 2017

Feb 15, 2018
SELL
$12.51 - $16.24 $736,276 - $955,805
-58,855 Reduced 53.01%
52,172 $751,000
Q3 2017

Nov 14, 2017
BUY
$11.74 - $15.78 $100,553 - $135,155
8,565 Added 8.36%
111,027 $1.67 Million
Q2 2017

Aug 14, 2017
BUY
N/A
102,462
102,462 $1.03 Million

Others Institutions Holding FOLD

# of Institutions
311
Shares Held
312M
Call Options Held
516K
Put Options Held
833K
View Full List

About AMICUS THERAPEUTICS, INC.

FOLD Quotes by TradingView
  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $2.69B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email